Showing results (101-110 of 177) with videos related to

Sort By:
Pageof 18
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|January 9, 2013
Nomogram to predict the probability of relapse in patients diagnosed with borderline ovarian tumorsAndreas Obermair, Amy Tang, Srinivas Kondalsamy-Chennakesavan, et al.
BMJ Open|May 11, 2019
How to train practising gynaecologists in total laparoscopic hysterectomy: protocol for the stepped-wedge IMAGINE trialAndreas Obermair, Nigel R Armfield, Nicholas Graves, et al.
Gynecologic Oncology|December 21, 2010
Hospital costs associated with adverse events in gynecological oncologySrinivas Kondalsamy-Chennakesavan, Louisa G Gordon, Karen Sanday, et al.
Breast Cancer Research and Treatment|July 9, 2003
Incidence of anaemia in breast cancer patients receiving adjuvant chemotherapyUrsula Denison, Jose Baumann, Christian Peters-Engl, et al.
Gynecologic Oncology|August 11, 2020
When will I feel normal again? Trajectories and predictors of persistent symptoms and poor wellbeing after primary chemotherapy for ovarian cancerVanessa L Beesley, Kate Webber, Christina M Nagle, et al.
Gynecologic Oncology|September 10, 2002
The impact of positive peritoneal washings and serosal and adnexal involvement on survival in patients with stage IIIA uterine cancerOliver Preyer, Andreas Obermair, Elisabeth Formann, et al.
The Australian & New Zealand Journal of Obstetrics & Gynaecology|November 10, 2007
Pap smear screening history of women with squamous cell carcinoma and adenocarcinoma of the cervixSok Cheon Pak, Martje Martens, Ruud Bekkers, et al.
International Journal of Cancer|September 2, 2024
Use of menopausal hormone therapy before and after diagnosis and ovarian cancer survival-A prospective cohort study in AustraliaRenhua Na, Susan J Jordan, Anna DeFazio, et al.
Gynecologic Oncology|May 3, 2005
The functional assessment of cancer-vulvar: reliability and validityMonika Janda, Andreas Obermair, David Cella, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|February 15, 2025
Phase 2b, open-label, single-arm, multicenter pilot study of the efficacy, safety, and tolerability of dostarlimab in women with early-stage mismatch repair-deficient endometrioid endometrial adenocarcinomaAndreas Obermair, Val Gebski, Jeffrey Goh, et al.
Pageof 18